A 68-year-old man from rural Maharashtra presents with lower urinary tract symptoms (LUTS) for 6 months—nocturia (×4), weak stream, and incomplete emptying. Digital rectal examination reveals a hard, irregular, nodular prostate with loss of the median sulcus. PSA is 12.5 ng/mL (normal <4). Transrectal ultrasound-guided biopsy of the right lobe shows adenocarcinoma with a Gleason score of 7 (3+4). Staging CT abdomen/pelvis and bone scan are normal. What is the most appropriate next step in management?

Explanation

## Clinical Context & Risk Stratification This patient has **intermediate-risk localized prostate cancer** based on: - PSA 12.5 ng/mL (10–20 range) - Gleason score 7 (3+4) — intermediate grade - cT2 disease (palpable nodule, loss of median sulcus) - No distant metastases (M0) **Key Point:** Intermediate-risk prostate cancer is defined by any ONE of: PSA 10–20, Gleason 7, or cT2 disease. ## Treatment Paradigm for Intermediate-Risk Disease For men with intermediate-risk localized prostate cancer and life expectancy >10 years, the standard of care is: | Modality | Role | Evidence | |----------|------|----------| | **EBRT + ADT (2–3 years)** | First-line curative intent | NCCN, ESMO, ASTRO guidelines; superior OS vs EBRT alone in intermediate-risk cohorts | | **Radical prostatectomy** | Alternative for younger men (<70 yrs) or those declining RT | Equivalent outcomes if performed by experienced surgeon | | **Active surveillance** | Only for low-risk disease (PSA <10, Gleason ≤6, cT1c) | NOT appropriate here due to Gleason 7 | | **TURP** | Palliative only for LUTS; does NOT treat cancer | Contraindicated as primary therapy | **High-Yield:** EBRT + ADT for 2–3 years is the **gold standard** for intermediate-risk prostate cancer in men with good performance status and life expectancy >10 years. [cite:NCCN Prostate Cancer Guidelines 2023] ## Why EBRT + ADT? 1. **Neoadjuvant ADT** (3–6 months before EBRT) reduces prostate volume, improves dose conformality, and eradicates micrometastases. 2. **Concurrent ADT during EBRT** enhances local control. 3. **Adjuvant ADT (2–3 years total)** improves overall survival and cancer-specific mortality in intermediate-risk men. 4. **Toxicity profile:** Acceptable erectile dysfunction and GI/GU toxicity rates in most series. **Clinical Pearl:** The combination of EBRT + long-term ADT reduces 5-year mortality by ~10% compared to EBRT alone in intermediate-risk disease.